Research ArticleDrug Discovery and Translational Medicine
DFL23448, A Novel Transient Receptor Potential Melastin 8–Selective Ion Channel Antagonist, Modifies Bladder Function and Reduces Bladder Overactivity in Awake Rats
Francesco A. Mistretta, Andrea Russo, Fabio Castiglione, Arianna Bettiga, Giorgia Colciago, Francesco Montorsi, Laura Brandolini, Andrea Aramini, Gianluca Bianchini, Marcello Allegretti, Silvia Bovolenta, Roberto Russo, Fabio Benigni and Petter Hedlund
Journal of Pharmacology and Experimental Therapeutics January 2016, 356 (1) 200-211; DOI: https://doi.org/10.1124/jpet.115.228684
Francesco A. Mistretta
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Andrea Russo
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Fabio Castiglione
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Arianna Bettiga
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Giorgia Colciago
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Francesco Montorsi
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Laura Brandolini
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Andrea Aramini
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Gianluca Bianchini
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Marcello Allegretti
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Silvia Bovolenta
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Roberto Russo
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Fabio Benigni
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Petter Hedlund
Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele, Milan, Italy (F.M.); Discovery Department, Research Centre Dompé Farmaceutici SpA, L’Aquila, Italy (L.B., A.A., G.B., M.A.); Discovery Biology, Axxam, Bresso, Milan, Italy (S.B.); Department of Pharmacy, Federico II University of Naples, Naples, Italy (R.R.); and Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Sweden (P.H.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
TRPM8 as a Drug Target in Models for Bladder Overactivity
Francesco A. Mistretta, Andrea Russo, Fabio Castiglione, Arianna Bettiga, Giorgia Colciago, Francesco Montorsi, Laura Brandolini, Andrea Aramini, Gianluca Bianchini, Marcello Allegretti, Silvia Bovolenta, Roberto Russo, Fabio Benigni and Petter Hedlund
Journal of Pharmacology and Experimental Therapeutics January 1, 2016, 356 (1) 200-211; DOI: https://doi.org/10.1124/jpet.115.228684
Research ArticleDrug Discovery and Translational Medicine
TRPM8 as a Drug Target in Models for Bladder Overactivity
Francesco A. Mistretta, Andrea Russo, Fabio Castiglione, Arianna Bettiga, Giorgia Colciago, Francesco Montorsi, Laura Brandolini, Andrea Aramini, Gianluca Bianchini, Marcello Allegretti, Silvia Bovolenta, Roberto Russo, Fabio Benigni and Petter Hedlund
Journal of Pharmacology and Experimental Therapeutics January 1, 2016, 356 (1) 200-211; DOI: https://doi.org/10.1124/jpet.115.228684
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement